# Xiaoyao San alleviates emotional distress - induced TNBC growth through augmenting intratumoral CD8+T cell infiltration mediated by Rela/NF-kB-Cxcl9 axis

**Authors:** Yuqi Liang, Yingchao Wu, Jieting Chen, Huan Shi, Zhuang Li, Juexiao Zeng, Junfeng Huang, Qian Zuo, Lingling Ye, Xue Song, Yan Dai, Yunlong Bai, Qianjun Chen

PMC · DOI: 10.3389/fimmu.2026.1762492 · Frontiers in Immunology · 2026-02-05

## TL;DR

Xiaoyao San, a traditional Chinese herbal formula, reduces stress-induced breast cancer growth by boosting immune cell activity through a specific molecular pathway.

## Contribution

Identifies the Rela/NF-kB-Cxcl9 axis as a novel mechanism through which Xiaoyao San enhances CD8+ T cell infiltration in emotional distress-induced TNBC.

## Key findings

- High-dose Xiaoyao San alleviates depression-like behaviors and suppresses tumor progression in a mouse model of ED-TNBC.
- Xiaoyao San activates the Rela/NF-kB-Cxcl9 axis, enhancing CD8+ T cell infiltration and cytotoxic activity in tumors.
- Active constituents of Xiaoyao San bind to Rela, promoting its nuclear translocation and Cxcl9 secretion in TNBC cells.

## Abstract

Emotional distress (ED) is closely associated with the progression of triple-negative breast cancer (TNBC). Xiaoyao San (XYS), a classical Chinese herbal prescription traditionally used for mood regulation, has demonstrated potential therapeutic efficacy in emotion-related breast cancer. However, the molecular mechanisms through which XYS mitigates ED-induced TNBC (ED-TNBC) remain insufficiently characterized. This study aimed to investigate the therapeutic effects of XYS on ED-TNBC and elucidate its underlying molecular mechanisms.

A TNBC mouse model subjected to chronic unpredictable mild stress (CUMS) was developed to simulate ED-TNBC conditions. The therapeutic efficacy of XYS at varying doses was evaluated through behavioral assessments and tumor growth analyses. Multi-omics analyses integrating network pharmacology, bioinformatics, and molecular dynamics simulations were employed to identify principal active constituents and key molecular targets of XYS. Transcriptomic profiling, in vivo and in vitro functional assays, and molecular biology experiments were conducted to delineate the molecular mechanisms underlying XYS-mediated regulation.

High-dose XYS markedly alleviated depression-like behaviors and suppressed ED-TNBC tumor progression, with no evident adverse effects observed. Transcriptomic and molecular analyses revealed that XYS enhanced CD8+ T cell infiltration and cytotoxic activity through activation of Cxcl9. The active constituents of XYS were found to bind directly to the transcription factor Rela. Subsequent experiments verified that Cxcl9 secretion from TNBC cells depends on Rela activity. In addition, XYS upregulated Rela expression and promoted its nuclear translocation.

XYS directly targets and activates the intratumoral Rela/NF-κB–Cxcl9 axis, promoting CD8+T cell infiltration and activation, thereby inhibiting the growth of ED-TNBS.

## Linked entities

- **Genes:** RELA (RELA proto-oncogene, NF-kB subunit) [NCBI Gene 5970], CXCL9 (C-X-C motif chemokine ligand 9) [NCBI Gene 4283]
- **Proteins:** CD8A (CD8 subunit alpha), NFKB1 (nuclear factor kappa B subunit 1)
- **Diseases:** triple-negative breast cancer (MONDO:0005494), breast cancer (MONDO:0004989)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Dnase1 (deoxyribonuclease I) [NCBI Gene 13419] {aka DNaseI, Dnl1}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Mki67 (antigen identified by monoclonal antibody Ki 67) [NCBI Gene 17345] {aka D630048A14Rik, Ki-67, Ki67}, Bcl2 (B cell leukemia/lymphoma 2) [NCBI Gene 12043] {aka Bcl-2, C430015F12Rik, D630044D05Rik, D830018M01Rik}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, Gzmb (granzyme B) [NCBI Gene 14939] {aka CCP-1/C11, CCP1, Ctla-1, Ctla1, GZB}, Fcgr2b (Fc receptor, IgG, low affinity IIb) [NCBI Gene 14130] {aka CD32, F630109E10Rik, Fc[g]RII, FcgRII, Fcgr2, Fcgr2a}, Fcgr3 (Fc receptor, IgG, low affinity III) [NCBI Gene 14131] {aka CD16}, RELA (RELA proto-oncogene, NF-kB subunit) [NCBI Gene 5970] {aka AIF3BL3, CMCU, NFKB3, p65}, Ptprc (protein tyrosine phosphatase receptor type C) [NCBI Gene 19264] {aka B220, CD45R, Cd45, L-CA, Ly-5, Lyt-4}, Rela (Rela proto-oncogene, NFKB subunit) [NCBI Gene 19697] {aka p65, p65 NF-kappa B, p65 NFkB}, Cxcl9 (C-X-C motif chemokine ligand 9) [NCBI Gene 17329] {aka CMK, Mig, MuMIG, Scyb9, crg-10}, Cd28 (CD28 antigen) [NCBI Gene 12487], Il2 (interleukin 2) [NCBI Gene 16183] {aka Il-2}, GZMB (granzyme B) [NCBI Gene 3002] {aka C11, CCPI, CGL-1, CGL1, CSP-B, CSPB}, Casp3 (caspase 3) [NCBI Gene 12367] {aka A830040C14Rik, AC-3, CASP-3, CC3, CPP-32, CPP32}, Ccl5 (C-C motif chemokine ligand 5) [NCBI Gene 20304] {aka MuRantes, RANTES, SISd, Scya5, TCP228}, Bax (BCL2-associated X protein) [NCBI Gene 12028], TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, Cxcl10 (C-X-C motif chemokine ligand 10) [NCBI Gene 15945] {aka C7, CRG-2, INP10, IP-10, IP10, Ifi10}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, Apc (APC, WNT signaling pathway regulator) [NCBI Gene 11789] {aka CC1, Min, mAPC}, Ifng (interferon gamma) [NCBI Gene 15978] {aka IFN-g, If2f, Ifg}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, Cxcl11 (chemokine (C-X-C motif) ligand 11) [NCBI Gene 56066] {aka Cxc11, H174, I-tac, Ip9, Itac, Scyb11}, D9Mgc45e (DNA segment, Chr 9, MRC UK Mouse Genome Centre 45 expressed) [NCBI Gene 28134] {aka CD3}, CXCL9 (C-X-C motif chemokine ligand 9) [NCBI Gene 4283] {aka CMK, Humig, MIG, SCYB9, crg-10}
- **Diseases:** deaths (MESH:D003643), CUMS (MESH:D000079225), cytotoxic (MESH:D064420), XYS (MESH:D009084), TNBC (MESH:D064726), gynecological disorders (MESH:D005831), depression (MESH:D003866), BC (MESH:D001943), inflammatory (MESH:D007249), melanoma (MESH:D008545), Tumor (MESH:D009369), non-small cell lung cancer (MESH:D002289), ED (MESH:D012128)
- **Chemicals:** penicillin (MESH:D010406), BE0309 (-), NO (MESH:D009614), sucrose (MESH:D013395), Naringenin (MESH:C005273), Fluoxetine (MESH:D005473), CO2 (MESH:D002245), DAPI (MESH:C007293), TNBS (MESH:D014302), Licochalcone A (MESH:C070840), PBS (MESH:D007854), Hydrogen (MESH:D006859), Isorhamnetin (MESH:C047368), alcohol (MESH:D000438), PVDF (MESH:C024865), formic acid (MESH:C030544), paraffin (MESH:D010232), Calycosin (MESH:C121707), methanol (MESH:D000432), streptomycin (MESH:D013307), xylene (MESH:D014992), nitrogen (MESH:D009584), paeoniflorin (MESH:C015423), TRIzol (MESH:C411644), water (MESH:D014867), CCK-8 (MESH:D012844), Kaempferol (MESH:C006552), SDS (MESH:D012967)
- **Species:** Paeonia lactiflora (Chinese peony, species) [taxon 35924], Atractylodes macrocephala (species) [taxon 265785], Homo sapiens (human, species) [taxon 9606], Wolfiporia cocos (species) [taxon 81056], Armenian hamster [taxon 10032], Mus musculus (house mouse, species) [taxon 10090], Mentha canadensis (American wild mint, species) [taxon 294733], Zingiber officinale (ginger, species) [taxon 94328]
- **Mutations:** P0010S, P0018S, C with 0
- **Cell lines:** Py230 — Mus musculus (Mouse), Malignant neoplasms of the mouse mammary gland, Cancer cell line (CVCL_AQ08), C57BL/6 — Mus musculus (Mouse), Transformed cell line (CVCL_C0MU), S2 — Drosophila melanogaster (Fruit fly), Spontaneously immortalized cell line (CVCL_Z232), HEK293T — Homo sapiens (Human), Transformed cell line (CVCL_0063)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12916637/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12916637/full.md

## References

56 references — full list in the complete paper: https://tomesphere.com/paper/PMC12916637/full.md

---
Source: https://tomesphere.com/paper/PMC12916637